# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Roche ((SIX: RO, ROG, OTCQX:RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of co...
Raymond James analyst Steven Seedhouse downgrades 89bio (NASDAQ:ETNB) from Outperform to Market Perform.
The "Jimmy Kimmel Live" drama coincided with reports of tit-for-tat maneuvering between the FCC and corporations desper...
Wolfe Research analyst Andy Chen downgrades 89bio (NASDAQ:ETNB) from Outperform to Peer Perform.
HC Wainwright & Co. analyst Andrew S. Fein downgrades 89bio (NASDAQ:ETNB) from Buy to Neutral and announces $14.5 price ...
Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Small caps rally 43% since ta...
Roche is acquiring 89bio for $2.4 billion plus potential milestone payouts, bolstering its pipeline with late-stage MASH drug p...